This is the 2nd times of price dipped to 54.5 before staging a strong rebound. I was waiting to top up at 53 cents.

Rebound so fast. Yoyo game?

Raider. What more to expect with 30% profit earned from Jaks in a month? lolz

Probability. Yeah. Better move up slowly. IBs love to issue call warrants to take advantage of volatility of share price movements.

CE issued by CIMB is expiring end of Jan 2020. Think they will press down the share price again after the QR announcement.

Takaful CC, CD and CF are expiring end of this month.

Based on HL Invest research report title " In a Bittersweet Spot " on 16 Sep 2019, it mentioned that 'As for its family bancatakaful business, credit-related products growth should taper and normalize from 3Q19 on wards, given contribution from Bank Rakyat on a full-year basis has come to a tail end, coupled with a high base effect ". However, It did not happen. Takaful remains on track of achieving double digits growth.

Family Fund Revenue growth QoQ
30 Sep 19 - 24%
30 Jun 19 - 34%
31 Mar 19 - 32%
31 Dec 18 - 50%
30 Sep 18 - 45%

30 Jun 18 - 8%
30 Mar 18 - 6%
31 Dec 17 - 0%
30 Sep 17 - 5%
30 Jun 17 - 3%

Easy money. Go go go!

Stock market is changing too fast including repercussions.

There’s an illustrative example published by IFRS.org in comparison between IFRS 4 and IFRS 17. ....The final profit and loss shows a slightly improvement whereas Revenue plunging due to different basis in recognizing revenue.

https://www.ifrs.org/-/media/project/insurance-contracts/ifrs-standard/ifrs-17-effects-analysis.pdf/
Page 83

unfavourable upcoming MFRS17 accounting change” as claimed by HL Invest. Is it really the new MFRS 17 impact to insurance company profit and loss? It seems like very very serious issues to insurance company...profit plunging??? Lolz

Here’s the summary explanation:

The presentation of the income statement also changes minorly, but the change is important. Written premiums are not important anymore it is now about services provided. So earned premiums are replaces by service income and service expenses. As the name implies the income and expenses connected to the services which the insurer has provided in the period. Also for the income statement will the specification change largely:

Specification whether the service income and expenses are connected to a service which was delivered in the past, current period or even future period
Just like the balance sheet do we also have to divide the changes of the insurance liability into Fair Value Approach, the Modified Retrospective Approach or the Full retrospective approach / regular contracts.

PAT
Dec 19 - ???
Sep 19 - 113m
Jun 19 - 80m
Mar 19 - 96m

Dec 18 - 90m
Sep 18 - 83m
Jun 18 - 50m
Mar 18 - 70m

Dec 17 - 56m
Sep 17 - 48m
Jun 17 - 44m
Mar 17 - 57m


Revenue
Dec 19 - ???
Sep 19 - 753m
Jun 19 - 673m
Mar 19 - 918m

Dec 18 - 702m
Sep 18 - 649m
Jun 18 - 542m
Mar 18 - 746m

Dec 17 - 518m
Sep 17 - 472m
Jun 17 - 485m
Mar 17 - 660m

Hard to cari makan if we follow IBs analysis. The information below may provide some clues about the quantum of net contributions earned next few quarters.

Net contribution earned for Family Fund
Dec 19 - ???
Sep 19 - 570m
Jun 19 - 433m
Mar 19 - 472m
Dec 18 - 466m
Sep 18 - 408m
Jun 18 - 335m
Mar 18 - 308m
Dec 17 - 303m
Sep 17 - 289m
Jun 17 - 301m

Net contribution earned for General Fund
Dec 19 - ???
Sep 19 - 170m
Jun 19 - 103m
Mar 19 - 129m
Dec 18 - 93m
Sep 18 - 112m
Jun 18 - 103m
Mar 18 - 115m
Dec 17 - 68m
Sep 17 - 85m
Jun 17 - 77m

Game over only if its future business prospects is gloomy and unable to report better QR.

Awaiting the company to announce better QR next month and completion of 2nd clinical trials for Herpa-P early next year.

It may take a bit of time for IB to admit that their projection underestimate the growth of Takaful. They have to arrange meetings and discussions to find out the reasons behind whereas we, retailers, are able to respond swiftly without a need to go through a lengthy process.

Many IB claimed that QR growth and profits might be normalised starting 3rd Qtr. The facts is that they were wrong in making such projection based on their prejudice assumptions.

It is not possible to achieve 100% correct in our decisions. What important is that when we know we are wrong and willing to initiate a change without care much of our ego. We have to follow trend to earn money in share market rather than fighting with the facts in real life.

Great QR. Buy before IB revise their new TP.

Redtone MTNS segment Contribution:

PBT
30 Sep 19 - ???
30 Jun 19 - 5.6m (2 months)
30 Apr 19 - 7.2m
31 Jan 19 - 1.9m
31 Oct 18 - (2.5)m
31 Jul 18 - (1.9)m
30 Apr 18 - (4.5)m

Turnover
30 Sep 19 - ???
30 Jun 19 - 18.7m (2months)
30 Apr 19 - 52.3m
31 Jan 19 - 23.7m
31 Oct 18 - 8.7m
31 Jul 18 - 9.7m
30 Apr 18 - 8m

Expecting good QR in next few quarters plus NFCP. Breaking RM 1 will become reality soon.

Dealing with fatty liver
https://www.pressreader.com/malaysia/the-star-malaysia-star2/20180417/282089162360026

" More new drugs emerge ever day, but even promising ones such as glucagon-like-peptide-1 receptor agonist are still in testing or trail stages....

https://clinicalresearch.my/the-journey-of-a-clinician-researcher-on-nafld-in-malaysia-from-epidemiology-to-non-invasive-assessment-to-treatment/

Epidemiology of NAFLD

The prevalence of NAFLD in the general population was estimated to be 23% based on a study using ultrasonography on health check individuals in a private medical centre in Petaling Jaya about a decade ago.(2)“The work by Professor Dato Dr. Goh Khean Lee and his colleagues, provided primary data on the estimated prevalence of NAFLD in the general population in Malaysia,” said Dr. Chan. Recently, the prevalence of NAFLD was found to be 57% based on a study using Fibroscan on health check individuals in a public medical facility in Kuala Lumpur. The study also found that 18% of the individuals had liver stiffness measurement consistent with excessive scarring in the liver.(3)“The figures from our latest work are indeed worrisome. More concerted efforts are needed to tackle obesity and obesity-related disease such as NAFLD,” he said. The group also reported that half of the patients with diabetes mellitus seen at their hospital clinic had NAFLD,(4)and 8% of the students at their faculty had NAFLD.(5)

New GMP factory:
Upon completion of the new GMP-compliant production facility, our production capacity for functional food is expected to increase from 0.69 million bottles and 0.69 million sachets to 3.43 million bottles and 3.43 million sachets.

The construction of the new GMP Plant had commenced in August 2017 and Phase 1 is expected to be completed by September 2019. Construction of Phase 2 will commence after completion of Phase 1.

Clinical trials on Ficus Cream products for skin lightening and We have completed the pre-clinical trial on Ficus microcarpa standardised extract contained in Ficus Cream products in 2016. We intend to undertake two clinical trials for Ficus Cream products in September 2019 and to complete both by July 2020. The clinical trials are to evaluate the effectiveness and safety of Ficus Cream for skin lightening and to explore other anti-ageing properties. The trials will be conducted on two different formulations containing the Ficus microcarpa standardised extract. Each clinical trial will be an 8-week trial and will involve a group of approximately 50 participants.

If the trials are successful and Ficus Cream products are clinically proven to be effective and safe for skin lightening, we expect to strengthen the products positioning as a skin lightening agent.

All these issues is merely targeting Anwar to pressure him making a wrong decision. Anwar can simply wait for another 7 months before launching full attack.

Demand outstripped supply suddenly. Uptrend has resumed?

1st clinical trial:

The first clinical trial was completed in January 2015. Our CRO has presented us the final report of the study. From the first clinical trial, Hepar-P Capsule was proven was proven safe for long term consumption with no adverse effects reported in patients. However, the efficacy could not be concluded as not all the patients consented to the liver biopsy at the end of the clinical trial. Only 6 patients out of the 50 patients consented to repeat the liver biopsy at the end of the clinical trial. The 6 patients showed improvement in liver enzymes. The major limitation of the first clinical trial is the relatively small sample size (50 patients) and the biopsy was not repeated for most of the patients after the completion of the treatment.

Extract from prospectus:

2nd clinical trial:
We initiated the second clinical trial for Hepar-P Capsule in December 2017 and are expected to complete in December 2019. The second clinical trial is to allow for a specific claim on the effectiveness of Hepar-P Capsule for the improvement of liver health. The second trial involves patients with non-alcoholic fatty liver as well and will be administered to a larger group of participants of approximately 200 participants to further evaluate its effectiveness for liver health.

3rd clinical trial:
Third clinical trial for Hepar-P Capsule as liver protection agent;
We expect to begin the third clinical trial for Hepar-P Capsule in October 2019 and to complete in December 2020. The third clinical trial involves patients with drug induced liver injury. The third clinical trial will be administered to a larger group of participants of approximately 300 participants to further evaluate the product’s effectiveness. The third clinical trial will be a 6-month trial involving participants with elevated liver enzymes level. If the trial is successful and Hepar-P Capsule is clinically proven to be effective, the third clinical trial will allow for more empirical data to be obtained to further promote and strengthen the product positioning as a liver protection agent.

Financial facts of Nova Wellness:
Price: 0.64
PER: 21x
Gearing: Nil
Dividend yield: 3.6% ( 2.3 cents per share)

Net cash generated from operating activities:
FY 30 Jun 2019 - 13.3m
FY 30 Jun 2018 - 7.1m

PAT
30 Sep 19 - ???
30 Jun 19 - 3.71m ( excluding IPO expenses, reversal of slow moving stock & interest received)
31 Mar 19 - 2.03m
31 Dec 18 - 3.08m
30 Sep 18 - 0.85m
30 Jun 18 - 2.41m
31 Mar 18 - 1.38m

Turnover
30 Sep 19 - ???
30 Jun 19 - 9.6m
31 Mar 19 - 7.2m
31 Dec 18 - 7.9m
30 Sep 18 - 4.8m
30 Jun 18 - 8.1m
31 Mar 18 - 4.7m

It seems like waking up now.

Able Dairies Mexico (Associate) is either seriously undervalued or something out of our expectation.

Original Investment in 40% Associate - RM 21 million (as shown in latest QR)
Additional subscriptions 3.13% - RM 23.4 million or USD 5.59 million (Cash outflow)

Is the estimated market value of Able Dairies Mexico skyrocketed to RM 750 million ( RM 23.4/3.13%) due to surging in land prices after the trade war?
Market Cap of Johotin is only RM 413 million now.


Reply to Query from Bursa
2) Basis and justification in arriving at the amount of USD5,589,427.43 for the Additional Subscription.
Answer:
The total cost of investment on newly incorporated company is to purchase land, construct building, purchase of machineries and equipment, which includes installation costs, water tank, piping, etc.

Accumulate on weakness. This is a dream chasers' stock. Rally will resume after a short period of consolidation.

Original investment in associate Able Daires Mexico costs RM 21 million for 40% stakes. Now, It costs RM 23 million to acquired additional 3.13% even before the new plant starting operation. How they arrive the figures? mind boggling.

Rally resumed so fast. Go go go!

Revenue and earnings are still trending upward and the beneficially from Budget, the price will be going up further.

Share price up like nobody business. First TP 76 cents.

If Hepar-P is able to complete 3rd clinical trials, MNC may come to take over Nova. lolz

Posted by shortinvestor77 > Oct 11, 2019 5:32 PM | Report Abuse

Clinical trial of Hepar-P Capsule ( is for the treatment of non-alcoholic fatty liver disease.
2015
Completed the first clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.
2017
Ready for the second clinical trial of Hepar-P Capsule for the treatment of non-alcoholic fatty liver disease.
http://nova.my/history

It may take years to get through 5 phases clinical trials .

Phases of clinical trials
A clinical trial is only done when there is good reason to believe that a new test or treatment may improve the care of patients. Before clinical trials, tests and treatments are assessed in preclinical research. Preclinical research is not done with people. It assesses the features of a test or treatment. For example, the research may aim to learn if a device is harmful to living tissue. Another aim may be to learn more about the chemical makeup of a drug.

After preclinical research, tests and treatments go through a series of clinical trials. Clinical trials assess if tests or treatments are safe for and work in people. Clinical trials have five phases. The phases are described next using the example of a new drug treatment:

Phase 0
Phase 0 trials are the first clinical trials done among people. They aim to learn how a drug is processed in the body and how it affects the body. In these trials, a very small dose of a drug is given to about 10 to 15 people.

Phase I
Phase I trials aim to find the best dose of a new drug with the fewest side effects. The drug will be tested in a small group of 15 to 30 patients. Doctors start by giving very low doses of the drug to a few patients. Higher doses are given to other patients until side effects become too severe or the desired effect is seen. The drug may help patients, but Phase I trials are to test a drug’s safety. If a drug is found to be safe enough, it can be tested in a phase II clinical trial.

Phase II
Phase II trials further assess safety as well as if a drug works. The drug is often tested among patients with a specific type of cancer. Phase II trials are done in larger groups of patients compared to Phase I trials. Often, new combinations of drugs are tested. Patients are closely watched to see if the drug works. However, the new drug is rarely compared to the current (standard-of-care) drug that is used. If a drug is found to work, it can be tested in a phase III clinical trial.

Phase III
Phase III trials compare a new drug to the standard-of-care drug. These trials assess the side effects of each drug and which drug works better. Phase III trials enroll 100 or more patients.

Often, these trials are randomized. This means that patients are put into a treatment group, called trial arms, by chance. Randomization is needed to make sure that the people in all trial arms are alike. This lets scientists know that the results of the clinical trial are due to the treatment and not differences between the groups. A computer program is often used to randomly assign people to the trial arms.

There can be more than two treatment groups in phase III trials. The control group gets the standard-of-care treatment. The other groups get a new treatment. Neither you nor your doctor can choose your group. You will also not know which group you’re in until the trial is over.

Every patient in a phase III study is watched closely. The study will be stopped early if the side effects of the new drug are too severe or if one group has much better results. Phase III clinical trials are often needed before the FDA will approve the use of a new drug for the general public.

Phase IV
Phase IV trials test new drugs approved by the FDA. The drug is tested in several hundreds or thousands of patients. This allows for better research on short-lived and long-lasting side effects and safety. For instance, some rare side effects may only be found in large groups of people. Doctors can also learn more about how well the drug works and if it’s helpful when used with other treatments.

Why Nova is allowed to sell hepar-p in the market since all clinical tests has not been passed?

shortinvestor77
Once Nova product hepar-p passes all clinical tests, the share price will boom a few folds.
10/10/2019 9:03 PM

MBMR has been sleeping for 2 months. When will it wake up?

The company is required to disclose any acquisition/disposal of interests in subsidiary or JV or Associate under QR note 11. Effect of Changes in the Composition of the Group.

"Investors must find out if CEO Andy Ang has sold his personal share in the joint venture to Jaks. Since he is controlling the company, he can make Jaks to buy his share without an EGM to seek the approval of shareholders."

JAKS has 51% equity interest in JAKS Island Circle Sdn Bhd in property development business. No acquisition of Non Controlling Interests as stated in latest QR Cash Flow Statement. Therefore, Jaks has not acquired any remaining stakes from Andy.

"1, Jaks and its CEO Andy Ang are in JV to develop the Star Media land. It is one of the largest property developments in KL. It consists of 2 office tower blocks in front and 3 high rise condominium at the back. All these are sitting on a 4 storey underground car parks. Due to late construction completion, Star has forfeited the Rm 50 million performance bank guarantee and the High Court has passed judgement. Jaks is now trying to put an injunction to delay the payment of the Rm 50 million. The case has gone to Appeal Court.

Investors must find out if CEO Andy Ang has sold his personal share in the joint venture to Jaks. Since he is controlling the company, he can make Jaks to buy his share without an EGM to seek the approval of shareholders."

Extracted from AR 2018 :
The current ongoing mixed development project at Section 13, Petaling Jaya known as Pacific Star achieved sales to-date of RM951 million (2017 : RM915 million), being 86% of the total gross domestic value (“GDV”) of approximately RM1.1 billion. The GDV and sales to-date included the Pacific Star Business Hub (“Business Hub”) which was sold to another subsidiary within the Group. The Pacific Star project is expected to complete by end- 2019 and the Group will take a step back from the property development sector for the time being in view of the current property market landscape. As at the end of March 2019, the Group has unbilled sales of RM203 million from its property development projects, giving the Group earnings visibility for the coming years.
The Business Hub at Pacific Star which is a four-storey retail and commercial centre, is expected to be completed in the second half of 2019 and will be operational before the year end. this commercial centre will serve the residents and offices from the surrounding established neighbourhood.


" Now Star and other buyers are demanding compensation for late completion under the Housing Ordinance. This will drag on for a long time until the project is completed. Even when Star Media project is completed, Jaks will have great difficulties to sell all the properties. "

DK. Is it Uncle experience not up to date?

"Jaks also has a coal power plant contract to generate electricity to sell to the Vietnamese Government. Jaks has sold 70% of the contract to a Chinese Company for Rm 440 million which is to be paid during the power plant construction. Jaks is now reporting profit from this Rm 440 million which has attracted so many investors. From my experience in power plant construction, even after the power plant construction is completed, it will take more than 1 years to test run the huge muti- billion $ system. "


Posted by DK66 > Oct 10, 2019 5:53 PM | Report Abuse

https://baijiahao.baidu.com/s?id=1636755112157630248&wfr=spider&am...

越南永新燃煤电厂一期BOT项目2号机组自投产以来，一直维持高负荷连续运行，发电量共计28.27亿度，负荷率为98.17%，等效可利用系数99.78%，各项指标优良。2号机组高负荷连续运行

Vinh Tan 1 power plant continuous high load for 200 days since commercial operation. No time lag after CO

You can refer to the interest expense 30 million in cash flow statement of AR 2018. Interest expenses capitalised in investment property in note 26. Finance Costs.

Posted by DK66 > Oct 10, 2019 7:30 PM | Report Abuse

Let me clarify, capitalized interest payments will not show up in the cash flow statement but added to the property development assets.

-----------------------------
Up_down An accountant can never hide interest payments as shown in the Cash Flow statement.

'Investors cannot see the amount of payment for interest charges for bank loan for the construction of the Star Media land because according to accounting rules, payment of interest can be capitalized.'
10/10/2019 7:23 PM

An accountant can never hide interest payments as shown in the Cash Flow statement.

'Investors cannot see the amount of payment for interest charges for bank loan for the construction of the Star Media land because according to accounting rules, payment of interest can be capitalized.'

My interpretation is not to drink too much XO as I did before. Who got so much XO to drink here? lolz


'My intention in writing this piece is to advise investors not to repeat the same mistake as I did before. I bought Jaks in anticipation of its future profit from its electricity power generation in Vietnam.'

I am quite surprised that Uncle is so interested in knowing the details of the accounts. It doesn't seem like him as a businessman in the share market.

Goodwill RM 148 million was actually existed even before 2013.


According to its 2nd quarter accounts, it reported the following which investors must verify:

1, Rm 148 million for good will. Who has taken this money?

2, Rm 642 million in investment properties.

3, Rm 280 million in Joint Venture

4, Rm 318 million long term long.

5, Rm 82 million current bank loan.

6, Rm 935 million trade and other payable.

7, Rm 82 million cash at the beginning of the period and Rm30 million end of the period.

How the share price can go up nicely if no strong operators get involved? This is the reality in share market and got nothing to hide.

Thanks for your info. I am quite sure some China funds are standing behind controlling Jaks. Kyy got no choice and had to let go his stakes last time. I am expecting Jaks to trade max 90 cents today and breaking RM 1 by end of the month. I did not expect such number of crowd is attracted... It seems there are too many contra players get involved.

Posted by Ooi Teik Bee > Oct 10, 2019 6:09 PM | Report Abuse

Posted by Up_down > Oct 10, 2019 5:58 PM | Report Abuse

Jaks is too wild today. With such huge volume...No eye see next week.

I was told China firm was interested to buy a block of Jaks shares a year ago, my VIP client expected the share price of Jaks will skyrocket up into the sky. However, it did not happen at the time.

The present up surge may imply someone is interested to buy a block of Jaks shares. I do not know, I just speculate only. The volume is very high now to make me to recall the event.

This information is what I heard a year ago.

Thank you.
Ooi